MAFLD in Egyptian non-dialysis CKD Patients: Frequency, fibrosis severity, and risk factors
PLOS One · 2025
DOI: 10.1371/journal.pone.0336568 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS One, 2025. Verfasst von Zienab M Saad und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Tropical Medicine, Faculty of Medicine, Minia University, Minya, Egypt. Hauptthemen laut MEDLINE: Renal Insufficiency, Chronic, Liver Cirrhosis, Fatty Liver, Non-alcoholic Fatty Liver Disease. Die Arbeit nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
The prevalence of Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD) in non-dialysis chronic kidney disease (CKD) patients remains underexplored, particularly in high-risk populations such as Egyptians with high rates of metabolic disorders.
Aims
This study aimed to determine the frequency of MAFLD in Egyptian non-dialysis CKD patients, assess liver fibrosis severity, and identify associated metabolic risk factors.
Methods
A cross-sectional study of 108 CKD patients was conducted, with participants stratified into MAFLD (n = 64) and non-MAFLD (n = 44) groups. Diagnostic criteria for MAFLD included hepatic steatosis (ultrasonography) and metabolic risk factors. Non-invasive fibrosis scores (NAFLD score, FIB-4 index, APRI score) and shear wave elastography were used to evaluate liver fibrosis.
Results
MAFLD prevalence was 59.25%. MAFLD patients exhibited significant associations with older age (56 ± 17.1 vs. 43 ± 17.1 years, p < 0.001 ), higher BMI (34.5 ± 6.2 vs. 27.2 ± 5.7 kg/m 2 , p < 0.001 ), diabetes (48.4% vs. 4.5%, p < 0.001 ), hypertension (68.7% vs. 22.7%, p < 0.001 ), and insulin resistance (HOMA-IR: 3.5 ± 3.6 vs. 1.45 ± 1.03, p < 0.001 ). MAFLD patients also had lower eGFR (40.5 ± 28.0 vs. 58.9 ± 39.9 mL/min/1.73 m 2 , p = 0.017 ) and higher liver stiffness (7.6 ± 1.8 vs. 6.9 ± 1.7 kPa, p = 0.047 ), with advanced fibrosis more prevalent in later CKD stages..
Conclusion
MAFLD is highly prevalent among non-dialysis CKD patients, driven by shared metabolic abnormalities and CKD severity. These findings highlight the bidirectional relationship between MAFLD and CKD, emphasizing the need for integrated screening and management strategies to mitigate progression risks in this population.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Tropical Medicine, Faculty of Medicine, Minia University, Minya, Egypt.
- Department of Internal Medicine, Faculty of Medicine, Minia University, Minya, Egypt.
- Department of Radiology, Faculty of Medicine, Minia University, Minya, Egypt.
- Department of Clinical Pathology, Faculty of Medicine, Minia University, Minya, Egypt.
ORCID-Profile: Hesham K H Keryakos
Zitieren
APA
Saad, Z. M., Keryakos, H. K. H., Hassanin, H. A., Higazi, M. M., Sayed, M. M., Ismail, D. E., & Abdelhalim, S. M. (2025). MAFLD in Egyptian non-dialysis CKD Patients: Frequency, fibrosis severity, and risk factors. PLOS One. https://doi.org/10.1371/journal.pone.0336568
Vancouver
Saad ZM, Keryakos HKH, Hassanin HA, Higazi MM, Sayed MM, Ismail DE, et al. MAFLD in Egyptian non-dialysis CKD Patients: Frequency, fibrosis severity, and risk factors. PLOS One. 2025. doi:10.1371/journal.pone.0336568
BibTeX
@article{Saad2025,
author = {Saad, Zienab M and Keryakos, Hesham K H and Hassanin, Hala A and Higazi, Mahmoud M and Sayed, Manar M and Ismail, Doaa E and Abdelhalim, Safaa M},
title = {MAFLD in Egyptian non-dialysis CKD Patients: Frequency, fibrosis severity, and risk factors},
journal = {PLOS One},
year = {2025},
doi = {10.1371/journal.pone.0336568}
}
EUVIMED